(Q34371248)

English

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

systematic review

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

George Dranitsaris

1

object named as

George Dranitsaris

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Susanne Schmitz

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Reuben J Broom

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

14 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1917-1926

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Meta-analysis for rare events

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Renal cell carcinoma: current status and emerging therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1510-5

21 January 2018

Axitinib for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24037486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-013-1510-5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34371248&oldid=2196559163"